Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT

Bone Marrow Transplantation volume 48, pages 50–55 (2013)Cite this article

Subjects

Abstract

The roles of angiogenesis and angiogenic factors after allogenic hematopoietic SCT (HSCT) and during acute GVHD (aGVHD) are not known. Studies on pediatric patients are extremely scarce. Levels of angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) were analyzed from blood samples of 67 consecutive patients. The levels were correlated with aGVHD grades, routine laboratory parameters and outcome. Pre-transplant Ang2 values correlated with the occurrence of intestinal aGVHD (P=0.009), whereas post-transplant measurements correlated with the severity of skin and liver aGVHD (P=0.03, P=0.04, respectively). Pre-transplant levels of VEGF were associated with the occurrence of skin aGVHD (P=0.04), whereas post-transplant levels correlated to the severity of intestinal aGVHD (P=0.04). High Ang2 levels were associated with shorter EFS (P=0.039) and increased non-relapse mortality (NRM) (P=0.009). In conclusion, higher Ang2 levels predict higher NRM and, with coexisting high VEGF, also shorter EFS after pediatric HSCT. Our results suggest that both pre- and post-transplant levels of Ang2 and VEGF seem to correlate to the clinical state of the patient. However, the pathophysiology of this connection needs further studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Carmeliet P, Jain RK . Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257.

    Article  CAS  Google Scholar 

  2. Li WW, Hutnik M, Gehr G . Antiangiogenesis in haematological malignancies. Br J Haematol 2008; 143: 622–631.

    Article  Google Scholar 

  3. Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, Kalantar G et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009; 23: 1039–1048.

    Article  CAS  Google Scholar 

  4. Podar K, Anderson KC . The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383–1395.

    Article  CAS  Google Scholar 

  5. Hu B, Cheng SY . Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 2009; 11: 111–116.

    Article  CAS  Google Scholar 

  6. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10: 813–815.

    Article  CAS  Google Scholar 

  7. Lunn RA, Sumar N, Bansal AS, Treleaven J . Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematol 2005; 10: 107–114.

    Article  CAS  Google Scholar 

  8. Min CK, Kim SY, Lee MJ, Eom KS, Kim YJ, Kim HJ et al. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 149–156.

    Article  CAS  Google Scholar 

  9. Penack O, Socie G, van den Brink MR . The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood 2011; 117: 4181–4189.

    Article  CAS  Google Scholar 

  10. Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U . Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer 2007; 48: 387–392.

    Article  Google Scholar 

  11. Hu SW, Cotliar J . Acute graft-versus-host disease following hematopoietic stem-cell transplantation. Dermat Ther 2011; 24: 411–423.

    Article  Google Scholar 

  12. Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  13. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1–39.

    Article  CAS  Google Scholar 

  14. Nachbaur D, Schumacher P, Auberger J, Clausen J, Kircher B . Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 942–947.

    Article  CAS  Google Scholar 

  15. Kim DH, Lee NY, Lee MH, Sohn SK . Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1408–1416.

    Article  CAS  Google Scholar 

  16. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956–964.

    Article  CAS  Google Scholar 

  17. Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008; 32: 904–912.

    Article  CAS  Google Scholar 

  18. Kumpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen W et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008; 112: 2139–2148.

    Article  Google Scholar 

  19. Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Ishida H et al. Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 766–774.

    Article  CAS  Google Scholar 

  20. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685–1692.

    Article  CAS  Google Scholar 

  21. Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W, Schweigerer L . Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001; 92: 756–760.

    Article  CAS  Google Scholar 

  22. Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004; 103: 2929–2935.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology and Stem Cell Transplantation, Children’s Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

    M Porkholm, U M Saarinen-Pihkala & S-M Kivivuori

  2. Department of Oncology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

    P Bono

Authors
  1. M Porkholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Bono
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U M Saarinen-Pihkala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S-M Kivivuori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S-M Kivivuori.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porkholm, M., Bono, P., Saarinen-Pihkala, U. et al. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant 48, 50–55 (2013). https://doi.org/10.1038/bmt.2012.101

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.101

Keywords

This article is cited by

Search

Advanced search

Quick links